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Abstract
Background
Limited evidence is available about the association between serum uric acid and sub-
stages of the spectrum from normoglycaemia to type 2 diabetes mellitus. We aimed to
investigate the association between serum uric acid and risk of prediabetes and type 2 dia-
betes mellitus.
Methods
Eligible participants of the Rotterdam Study (n = 8,367) were classified into mutually
exclusive subgroups of normoglycaemia (n = 7,030) and prediabetes (n = 1,337) at
baseline. These subgroups were followed up for incident prediabetes (n = 1,071) and
incident type 2 diabetes mellitus (n = 407), respectively. We used Cox proportional
hazard models to determine hazard ratios (HRs) for incident prediabetes among individu-
als with normoglycaemia and incident type 2 diabetes mellitus among individuals with
prediabetes.
Results
The mean duration of follow-up was 7.5 years for incident prediabetes and 7.2 years for inci-
dent type 2 diabetes mellitus. A standard deviation increment in serum uric acid was signifi-
cantly associated with incident prediabetes among individuals with normoglycaemia (HR
1.10, 95% confidence interval (CI) 1.01; 1.18), but not with incident type 2 diabetes mellitus
among individuals with prediabetes (HR 1.07, 95% CI 0.94; 1.21). Exclusion of individuals
who used diuretics or individuals with hypertension did not change our results. Serum uric
acid was significantly associated with incident prediabetes among normoglycaemic women
(HR 1.13, 95% CI 1.02; 1.25) but not among normoglycaemic men (HR 1.08, 95% CI 0.96;
1.21). In contrast, serum uric acid was significantly associated with incident type 2 diabetes
mellitus among prediabetic men (HR 1.23, 95% CI 1.01; 1.48) but not among prediabetic
women (HR 1.00, 95% CI 0.84; 1.19).
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Conclusions
Our findings agree with the notion that serum uric acid is more closely related to early-phase
mechanisms in the development of type 2 diabetes mellitus than late-phase mechanisms.
Introduction
Uric acid is generated during nucleotide and adenosine triphosphate (ATP) metabolism and
comprises the end product of human purine metabolism.[1] We have previously demonstrated
in a large population-based cohort study that elevated serum levels of uric acid are associated
with increased risk of type 2 diabetes mellitus (DM) independently of other risk factors.[2]
This association has since then been replicated in many other prospective studies and subse-
quent meta-analyses.[3–6] In addition, serum uric acid has been associated with various car-
diovascular and metabolic conditions such as hypertension, obesity, heart failure and atrial
fibrillation in large population-based studies.[7]
Prediabetes is a disorder of glucose homeostasis characterized by impaired glucose toler-
ance or impaired fasting glucose. These are both reversible stages of intermediate hyperglycae-
mia that provide an increased risk of type 2 DM.[8] Prediabetes can therefore be regarded as
an important reversible stage that could lead to type 2 DM, and early identification of predia-
betes might contribute to the prevention of type 2 DM. Despite its established association with
incident type 2 DM, serum uric acid has not been studied extensively in relation to incident
prediabetes in individuals with normoglycaemia or incident type 2 DM in individuals with
established prediabetes.
Therefore, the objective of the present study is to determine whether serum uric acid is
associated with incident prediabetes among normoglycaemic individuals and type 2 DM
among prediabetic individuals. This study is performed within the framework of the Rotter-
dam Study, a large population-based prospective cohort study of participants aged 45 years
and older.[9]
Materials and methods
The Rotterdam Study
The methodology of the Rotterdam Study has been outlined extensively elsewhere.[9] Briefly,
the study initially consisted of 7,983 residents of the Ommoord district aged 55 years and over
in the city of Rotterdam, the Netherlands (RS-I). Following extension of the cohort in 2000
(RS-II), when individuals who had become 55 years of age or moved into the district since the
study start were added to the cohort, and 2006 (RS-III), when individuals aged 45–54 years
also became eligible for participation, the total number of subjects was 14,926 by the end of
2008.[9] These participants undergo physical examinations at the Rotterdam Study research
facility and home interviews every 3–4 years. Data is collected on health status, risk factors for
various diseases common in the elderly, anthropometric characteristics, incident disease and
cause-specific mortality.[9] The Medical Ethics Committee of the Erasmus Medical Centre
Rotterdam and the review board of the Dutch Ministry of Health, Welfare and Sport have
approved this population-based cohort study, and all participants have provided written
informed consent. For the purposes of this analysis, we combined data from cohorts RS-I
(using the third visit in 1997–1999 as baseline), RS-II (baseline visit 2000–2001) and RS-III
(baseline visit 2006–2009) of the Rotterdam Study.
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Definition of type 2 diabetes mellitus, prediabetes and normoglycaemia
As per the Rotterdam Study protocol and WHO guidelines, type 2 DM was defined as having a
fasting plasma glucose level 7.0 mmol/L, a non-fasting plasma glucose 11.1 mmol/L, the
use of oral anti-diabetic medication or insulin, treatment by diet with type 2 DM as an indica-
tion and/or being registered by a general practitioner as having type 2 DM.[10, 11] Prediabetes
was defined as a fasting plasma glucose level 6.0–6.9 mmol/L or a non-fasting plasma glucose
level 7.7–11.1 mmol/L, in addition to absence of all type 2 DM criteria. Normoglycaemia was
defined as a fasting plasma glucose level 6.0 mmol/L and absence of any of the above criteria
for prediabetes and type 2 DM. Fasting blood samples were obtained by means of venipunc-
ture at the Rotterdam Study research facility. The samples were stored at −80˚C in 5 mL ali-
quots. Within one week of sampling, glucose levels were measured by means of the glucose
hexokinase method.[12] All measurements were performed at the clinical chemistry laboratory
of Erasmus Medical Center, Rotterdam.
Measurement of serum uric acid
Serum uric acid was determined in non-fasting blood samples, centrifuged for 10 minutes at
3,000 RPM and then stored for one week at -20˚C. Uric acid activity was determined using a
Kone Diagnostica reagent kit and a Kone auto-analyser. After every 10 samples, 3 control sam-
ples were included to check calibration. If the average values of the control samples were not
within 2.5% of the true value in each run of 100 samples, this run was repeated. Day-by-day
variation had to be within 5% of this average value.
Covariates
In our study, the following covariates are considered: age, sex, body mass index (BMI), smok-
ing status, daily alcohol intake, total serum cholesterol, serum HDL cholesterol, systolic blood
pressure, serum insulin, serum glucose, hypertension (defined as having a systolic blood
pressure > 140 mmHg, a diastolic blood pressure > 100 mmHg or receiving blood-pressure
lowering medication with “hypertension” as an indication), physical activity, use of diuretics
and estimated glomerular filtration rate (eGFR). Data on serum glucose, total serum choles-
terol, serum HDL-cholesterol, serum insulin, blood pressure and eGFR were obtained at base-
line by means of venipuncture, performed during participants’ visits to the Rotterdam Study
research facility. Anthropometric characteristics were also recorded at the Rotterdam Study
research facility. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collab-
oration (CKD-EPI) equation.[13] The disease status with respect to type 2 DM and prediabetes
was ascertained through follow-up using general practitioners’ records and hospital discharge
letters, collected as part of the Rotterdam Study. Physical activity was assessed at baseline by
means of a modified version of the Zutphen Study Physical Activity Questionnaire and the
LASA Physical Activity Questionnaire.[9] Metabolic equivalents of task (MET) hours per week
were calculated based on time spent in light, moderate and vigorous activity. Data concerning
the use of medication, alcohol consumption and smoking at baseline was obtained through
Rotterdam Study home interviews and, for medication, consulting pharmacy dispensing
records.
Statistical analysis
To determine the association between serum uric acid and risk of incident prediabetes or inci-
dent type 2 DM, Cox proportional hazards regression was performed with serum uric acid as
the primary dependent variable and either incident prediabetes or incident type 2 DM as the
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response variable. The timescale in these models is follow-up time in years from baseline to
either of the clinical endpoints, death, loss-to-follow-up or January 1st, 2012. Models adjusted
only for age, sex and cohort as well as multivariable-adjusted Cox models were designed. The
confounders BMI, smoking status, daily alcohol intake, total serum cholesterol, serum HDL
cholesterol, systolic blood pressure, serum insulin, serum glucose, hypertension status, physi-
cal activity, use of diuretics and eGFR, selected based on previous literature, were added to the
models adjusted for age, sex and cohort incrementally. The covariates serum insulin level,
serum glucose level, daily alcohol intake and physical activity were log-transformed in the
analyses because they displayed non-normality. Non-linearity was accounted for by inclusion
of polynomial terms in the regression models if necessary. Interaction of uric acid with age
and sex was investigated by introducing the product of the variables age and sex with uric acid
to the regression models. Five-fold multiple imputation was performed to reduce bias that
could arise from missing values. The results of our analyses are presented as hazard ratios
(HR) with corresponding 95% confidence intervals. A p-value < 0.05 was considered statisti-
cally significant. Analyses were performed using SPSS Statistics version 21 (IBM Corp.,
Armonk, New York, USA) and R version 3.2.4 (The R foundation for Statistical Computing,
Vienna, Austria).
Results
The total study population eligible for analysis (n = 8,367) was divided into two mutually
exclusive subgroups: a subgroup with normoglycaemia at baseline (n = 7,030) and a subgroup
with prevalent prediabetes at baseline (n = 1,337). The selection procedure of our study popu-
lation and the subgroups is outlined in Fig 1. Baseline characteristics of the study population
are presented in Table 1.
Over a mean follow-up time of 7.5 years, 1,071 individuals with normoglycaemia at baseline
developed prediabetes (incidence rate 20.2 per 1,000 person-years). In this analysis, the per-
centage of individuals who were lost to follow up was 0.6% (40 out of 7,030 individuals). The
results of our analysis of the association between serum uric acid and incident prediabetes are
presented in Table 2. We found a significant association between serum uric acid and incident
prediabetes within individuals who were normoglycaemic at baseline in a model adjusted only
for age, sex and cohort (HR 1.31 per SD increment, 95% confidence interval (CI) 1.23; 1.40).
This association was attenuated but remained significant in the multivariable-adjusted model
(HR 1.10, 95% CI 1.01; 1.18). Performing separate analyses for men and women, we found
that the association between serum uric acid and incident prediabetes was present in both men
(HR 1.28, 95% CI 1.16; 1.41) and women (HR 1.34, 95% CI 1.23; 1.45) in models adjusted for
age and cohort (Table 3). After multivariable adjustment, serum uric acid was significantly
associated with incident prediabetes among women (HR 1.13, 95% CI 1.02; 1.25) but not
among men (HR 1.08, 95% CI 0.96; 1.21). Exclusion of individuals who use diuretics or indi-
viduals with hypertension did not materially change our findings (Table 4). The association
failed to reach statistical significance upon exclusion of individuals with a BMI 25 (HR 1.14,
95% CI 0.98; 1.33). In the multivariable-adjusted model we also analysed serum uric acid in
quartiles, providing quartile-specific HRs relative to the first quartile (Fig 2).
A total of 407 individuals with prediabetes at baseline developed type 2 DM over a mean fol-
low-up time of 7.2 years (incidence rate 42.4 per 1,000 person-years). In this analysis, the per-
centage of individuals who were lost to follow up was 0.4% (6 out of 1,337 individuals). Serum
uric acid was significantly associated with incident type 2 DM in individuals with prediabetes in
a model adjusting only for age, sex and cohort (HR 1.17, 95% CI 1.06; 1.30), but this association
weakened and was not statistically significant in the multivariable-adjusted model (HR 1.07,
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95% CI 0.94; 1.21) (Table 2). In sex-specific analyses, the association was significant among
men (HR 1.19, 95% CI 1.01; 1.40), and women (HR 1.18, 95% CI 1.03; 1.35) in models adjusted
for age and cohort (Table 3). After multivariable adjustment, serum uric acid was significantly
associated with incident type 2 DM among men (HR 1.23, 95% CI 1.01; 1.48) but not among
women (HR 1.00, 95% CI 0.84; 1.19). Exclusion of diuretic users, individuals with hypertension
or individuals with a BMI 25 did not change our findings (Table 4). No significant difference
was observed in any serum uric acid quartile compared to the first quartile (Fig 2).
Discussion
We have found that higher serum uric acid levels are associated with an increased risk of inci-
dent prediabetes in individuals with normoglycaemia aged 45 years or over, independently of
Fig 1. Selection of the study population.
https://doi.org/10.1371/journal.pone.0179482.g001
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Table 1. Baseline characteristics of the study population.
Normoglycaemia at
baseline
n = 7,030
Missing data
(%)
Prediabetes at
baseline
n = 1,337
Missing data
(%)
Age (years) 64.2 (9.7) 0.0% 66.6 (9.4) 0.0%
Sex • Male (%)
• Female (%)
• 2,890 (41.1%)
• 4,140 (58.9%)
0.0% • 665 (49.7%)
• 672 (50.3%)
0.0%
Body Mass Index 26.7 (3.9) 0.7% 28.5 (4.4) 0.6%
Serum Total Cholesterol (mmol/L) 5.8 (1.0) 0.0% 5.8 (1.0) 0.2%
Serum HDL (mmol/L) 1.4 (0.4) 0.6% 1.3 (0.4) 0.8%
Systolic Blood Pressure (mmHg) 137.2 (20.5) 0.5% 145.4 (20.8) 0.2%
Serum Insulin (pmol/L)a 66.0 (44.0) 0.2% 93.0 (67.0) 0.1%
Alcohol Consumption (g/day)ab 10.1 (12.6) 30.6% 13.7 (17.7) 35.2%
• Active (%)
• Former or Never
(%)
• 6,008 (85.2%)
• 975 (14.1%)
0.7% • 1,154 (86.3%)
• 176 (13.2%)
0.5%
Smoking • Active (%)
• Former or Never
(%)
• 1,236 (17.6%)
• 5,794 (82.4%)
0.7% • 237 (17.7%)
• 1,100 (82.3%)
0.4%
Hypertensionc • Yes (%)
• No (%)
• 3,981 (56.6%)
• 3.049 (43.4%)
1.3% • 1,000 (74.8%)
• 337 (25.2%)
0.7%
Use of diuretics • Yes (%)
• No (%)
• 581 (8.3%)
• 6,449 (91.7%)
2.9% • 199 (14.9%)
• 1,138 (85.1%)
3.1%
Serum Glucose (mmol/L)a 5.3 (0.6) 0.0% 6.3 (0.4) 0.2%
Estimated Glomerular Filtration Rate (mL/
min/1.73m2)
79.9 (15.7) 1.2% 77.4 (16.1) 0.5%
Metabolic Equivalents of Task (hours/
week)a
71.6 (64.5) 11.6% 68.7 (64.0) 10.2%
Serum Uric Acid (mmol/L) 0.31 (0.07) n/a 0.35 (0.08) n/a
Variables are presented as mean (standard deviation) unless otherwise indicated.
aVariable is presented as median (interquartile range).
bMedian alcohol consumption applies only to active drinkers.
cHypertension is defined as having a systolic blood pressure > 140 mmHg, a diastolic blood pressure > 100 mmHg or receiving blood-pressure lowering
medication with “hypertension” as an indication.
https://doi.org/10.1371/journal.pone.0179482.t001
Table 2. The association between serum uric acid and incidence of prediabetes and type 2 diabetes mellitus.
Incident prediabetes in normoglycaemic individuals P-value Incident type 2 DM in prediabetic individuals P-value
Model 1a 1.31 (1.23; 1.40) < 0.001 1.17 (1.06; 1.30) 0.002
Model 2b 1.30 (1.21; 1.40) < 0.001 1.21 (1.08; 1.35) 0.001
Model 3c 1.10 (1.01; 1.18) 0.022 1.07 (0.94; 1.21) 0.330
Results are presented as Hazard Ratio (95% confidence interval) for a standard deviation increment in serum uric acid.
aModel 1: adjusted for age, sex and Rotterdam Study cohort.
bModel 2: model 1 + hypertension status, serum total cholesterol, eGFR, MET-hours per week, systolic blood pressure and use of diuretics.
cModel 3: model 2 + daily alcohol intake, serum HDL, smoking status, BMI, serum glucose and serum insulin.
https://doi.org/10.1371/journal.pone.0179482.t002
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confounders. No significant association was observed between serum uric acid and incident
type 2 DM in individuals with prediabetes after multivariable adjustment.
The result with relation to incident prediabetes is consistent with previous research on this
subject using impaired fasting glucose as an endpoint.[14–17]. This could indicate that serum
uric acid is more closely associated with early-phase rather than late-phase mechanisms that
play a role in the development of type 2 DM. Typically, insulin resistance impairs pancreatic β-
cell physiology and compensatory mechanisms, thereby inducing β-cell dysfunction as a con-
sequence.[18] Insulin resistance could therefore be regarded as a reflection of early mecha-
nisms that contribute to the development of type 2 DM, whereas β-cell dysfunction reflects the
influence of late-stage mechanisms.[19] Currently, not much evidence is available concerning
the relation between serum uric acid and pancreatic β-cell function. Tang and colleagues
found an independent positive association between serum uric acid levels and residual pancre-
atic β-cell function.[20] In their cross-sectional analysis of 1,021 individuals with type 2 DM,
they observed that patients with higher serum uric acid had greater insulin secretion ability in
early disease stages, but their residual β-cell function decayed more quickly. The authors sug-
gest that this increased insulin secretion might be a compensatory mechanism to overcome
initial insulin resistance. In addition, Shimodaira and colleagues observed a significant nega-
tive association between serum uric acid and disposition index, a measure of pancreatic β-cell
function, in a cross-sectional analysis among non-diabetic Japanese women after adjustment
for age, BMI, systolic blood pressure, HbA1c, serum triglyceride level, serum HDL level and
Table 3. The association between serum uric acid and incidence of prediabetes and type 2 diabetes mellitus, stratified by gender.
Model Incident prediabetes in normoglycaemic individuals P-value Incident type 2 diabetes in prediabetic individuals P-value
Men 1a 1.28 (1.16; 1.41) < 0.001 1.19 (1.01; 1.40) 0.038
2b 1.26 (1.13; 1.40) < 0.001 1.30 (1.09; 1.56) 0.004
3c 1.08 (0.96; 1.21) 0.216 1.23 (1.01; 1.48) 0.039
Women 1a 1.34 (1.23; 1.45) < 0.001 1.18 (1.03; 1.35) 0.015
2b 1.35 (1.23; 1.48) < 0.001 1.19 (1.02; 1.38) 0.027
3c 1.13 (1.02; 1.25) 0.024 1.00 (0.84; 1.19) 0.877
Results are presented as Hazard Ratio (95% confidence interval) for a standard deviation increment in serum uric acid.
aModel 1: adjusted for age, sex and Rotterdam Study cohort.
bModel 2: model 1 + hypertension status, serum total cholesterol, eGFR, MET-hours per week, systolic blood pressure and use of diuretics.
cModel 3: model 2 + daily alcohol intake, serum HDL, smoking status, BMI, serum glucose and serum insulin.
https://doi.org/10.1371/journal.pone.0179482.t003
Table 4. Subgroup analyses for the association between serum uric acid and incident prediabetes and incident type 2 diabetes mellitus.
Incident prediabetes in normoglycaemic
individuals
P-value Incident type 2 DM in prediabetic
individuals
P-value
Exclusion of participants who use
diuretics
1.11 (1.02; 1.21) 0.016 1.05 (0.92; 1.21) 0.497
Exclusion of participants with
hypertension
1.16 (1.00; 1.34) 0.045 1.14 (0.84; 1.56) 0.412
Exclusion of participants with a
BMI 25
1.14 (0.98; 1.33) 0.097 1.10 (0.75; 1.61) 0.647
Results are presented as multivariable-adjusted Hazard Ratios (95% confidence interval) for a standard deviation increment in serum uric acid, adjusted for
age, sex, Rotterdam Study cohort, hypertension status, serum total cholesterol, eGFR, MET-hours per week, systolic blood pressure, use of diuretics, daily
alcohol intake, serum HDL, smoking status, BMI, serum glucose and serum insulin.
https://doi.org/10.1371/journal.pone.0179482.t004
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use of antihypertensive or antilipidemic drugs.[21] However, no definitive conclusions regard-
ing the association between serum uric acid and pancreatic β-cell function can be drawn at
this point. Further population-based, prospective studies investigating this association are war-
ranted. Although the association between serum uric acid and incident prediabetes was not
significant among individuals with BMI < 25, this finding is most likely due to a lack of statis-
tical power, because individuals with a BMI 25 constitute over half of our sample size in this
subgroup.
Serum uric acid has been investigated in relation to incident type 2 DM in individuals with
impaired fasting glucose by Kramer and colleagues, who found a significant association (OR
1.75, 95% CI 1.1; 2.9) after adjusting for various confounders in study population with charac-
teristics similar to ours.[22] We were not able to replicate this finding in our analysis, in which
Fig 2. Quartile-specific hazard ratios for serum uric acid in association with incident prediabetes and
incident type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pone.0179482.g002
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we had a considerably larger sample available and were able to adjust for a more comprehen-
sive set of confounding variables. It is possible that residual confounding in the previous study
could account for this difference, because Kramer and colleagues were unable to adjust for
smoking status and serum HDL level. These covariates were particularly impactful in our mul-
tivariable-adjusted model. Excluding these covariates from the model yields an increase in the
effect estimate (HR 1.13, 95% CI 1.00; 1.27) compared to the model which includes them (HR
1.07, 95% CI 0.94; 1.21). We also observe a steep decrease in the estimated hazard ratio for
incident type 2 diabetes between model 2 and 3 in our analysis. The variable that is responsible
for most of this decrease is serum HDL. It has been demonstrated that serum HDL is associ-
ated with plasma glucose levels and that it is strongly inversely associated with serum uric acid
levels.[23, 24] Therefore, serum HDL can be regarded as a particularly strong confounder of
this association.
There have been conflicting results reported in the literature about a possible sex-specific
nature of the association between serum uric acid and impaired fasting glucose.[16, 17] In our
study, we observe that serum uric acid is significantly associated with incident prediabetes
among normoglycaemic women, but not among normoglycaemic men. Several studies report
that the association between serum uric acid and glucose-related endpoints is especially pro-
nounced among women.[15, 16, 25, 26] The difference between men and women with relation
to incident prediabetes in our study can likely be attributed to residual confounding. We also
have fewer events among men (n = 439) than among women (n = 632) in this analysis, which
might lead to more imprecision in our estimated hazard ratio for men.
In contrast to this finding relating to incident prediabetes, serum uric acid was significantly
associated with incident type 2 diabetes among men with prediabetes, but not among women
with prediabetes in our study after multivariable adjustment. This observation was despite the
fact that the number of events was higher among women (n = 222) than among men (n = 185)
in this analysis. No other study has investigated the relation between serum uric acid and type
2 diabetes specifically among men with established glucose intolerance. Our result might sug-
gest that serum uric acid affects women more strongly in the early stages of glucose intolerance
development, whereas it affects men more strongly in more advanced stages. Potential biologi-
cal mechanisms underlying this phenomenon have not yet been investigated in the literature,
and further research is warranted.
Our findings build on the conclusion of a report by Kodama and colleagues, who per-
formed a meta-analysis on the association between serum uric acid and incident type 2 diabe-
tes in populations not stratified by glucose tolerance status (normoglycaemia or prediabetes)
at baseline.[27] They conclude that serum uric acid is significantly associated with incident
type 2 diabetes mellitus across 11 cohort studies, and that their result should encourage other
studies to identify sub-populations for which the association might be especially important.
We report that serum uric acid appears to be most strongly associated with the early stages of
the development of type 2 diabetes. A similar meta-analysis by Jia and colleagues also found a
positive association between serum uric acid and a combined endpoint of incident impaired
fasting glucose and incident type 2 diabetes.[5] Our results further characterize the association
between serum uric acid and glucose intolerance by treating incident prediabetes and incident
type 2 diabetes as separate endpoints.
The strengths of our study include its prospective nature, which minimizes the chance of
reverse causation, its long follow-up time and our ability to adjust for a large set of confound-
ers. We provide a comprehensive overview of the relation between serum uric acid and differ-
ent sub-stages on the spectrum between normoglycaemia and type 2 DM. However, our study
population consisted of mainly elderly individuals and roughly 95% of our participants were of
Caucasian ethnicity. Therefore, our results cannot be generalized to populations with a
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different composition without further consideration. Finally, we cannot exclude the possibility
of residual confounding, although the fact that we adjusted for many covariates should mini-
mize the chance of this type of bias.
In conclusion, serum uric acid was independently and positively associated with incident
prediabetes in individuals with normoglycaemia but not with incident type 2 DM in individu-
als with prediabetes in a large population-based cohort of individuals aged 45 years and over.
Our results indicate that serum uric acid might be more closely associated with early-phase
pathogenic mechanisms that contribute to the development of type 2 DM rather than late-
phase mechanisms.
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